Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 12/20 | 0.47 |
| ▸ | MMP9 | P14780 | 12/20 | 0.47 |
| ▸ | MMP3 | P08254 | 10/20 | 0.47 |
| ▸ | MMP13 | P45452 | 10/20 | 0.47 |
| ▸ | MMP1 | P03956 | 9/20 | 0.47 |
| ▸ | MMP7 | P09237 | 9/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839738 | 1.00 | KDM4E (0.49) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL3529082 | 0.84 | CA2 (0.40) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL3529081 | 0.84 | CA2 (0.40) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL28757910 | 0.84 | CA2 (0.40) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL18412644 | 0.81 | CA14 (0.43) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL13048839 | 0.81 | CA14 (0.43) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL13049836 | 0.81 | CA14 (0.43) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL29612792 | 0.81 | KDM4E (0.49) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL29613045 | 0.80 | MME (0.40) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL13612445 | 0.79 | KDM4E (0.47) | KDM4EMMP2MMP9MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440882-B2 | Process for the preparation of dexmethyl phenidate hydrochloride | HARMAN FINOCHEM LIMITED (IN) | 2022-09-13 | — | — | US | claimed |
| US-20230339930-A1 | Antiviral Heteroaryl Ketone Derivatives | PFIZER INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339930-A1 | Antiviral Heteroaryl Ketone Derivatives | PFIZER INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3342599-B1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO LTD (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-10086634-B2 | Heat-sensitive recording material | SANKO CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3342599-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Sanko Co., Ltd. (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-7132420-B2 | Aspartic protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1140846-B1 | ASPARTIC PROTEASE INHIBITORS | US GOV HEALTH & HUMAN SERV (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1140846-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040558-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-0642530-B1 | DERIVATIVES OF DOLASTATIN | BASF AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0642530-A1 | DERIVATIVES OF DOLASTATIN | BASF Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | ASIC1, SCN1A, NPR1 | KDM4E 3830/4885MMP2 3267/4885MMP9 3602/4885 |
| US-10086634-B2 | Heat-sensitive recording material | ASIC1, SCN1A, NPR1 | KDM4E 3621/4885MMP2 3320/4885MMP9 3339/4885 |
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | KDM4E 3396/4885MMP2 45/4885MMP9 26/4885 |
| US-20230339930-A1 | Antiviral Heteroaryl Ketone Derivatives | ACE2, ZC3HAV1, SARS1 | KDM4E 936/4885MMP2 2552/4885MMP9 2259/4885 |
| US-11440882-B2 | Process for the preparation of dexmethyl phenidate hydrochloride | SLC6A3, COMT, DAO | KDM4E 466/4885MMP2 695/4885MMP9 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.